摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

水绫霉素 | 26055-63-0

中文名称
水绫霉素
中文别名
——
英文名称
aquayayamycin
英文别名
aquayamycin;(3R,4aR,12bS)-9-[(2R,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]-3,4a,8,12b-tetrahydroxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1,7,12-trione
水绫霉素化学式
CAS
26055-63-0
化学式
C25H26O10
mdl
——
分子量
486.475
InChiKey
KCOULPRVOZDQEL-IFNZWHIZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    782.2±60.0 °C(Predicted)
  • 密度:
    1.65±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    35
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    182
  • 氢给体数:
    6
  • 氢受体数:
    10

SDS

SDS:ff36dfa869892e520ac79c0c3badd0e6
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    水绫霉素偶氮二异丁腈三苯基氢化锡 作用下, 以 甲苯 为溶剂, 反应 1.0h, 以15%的产率得到urdamycinone B
    参考文献:
    名称:
    新型糖修饰的安古环素-抗生素的合成和生物学评估。
    摘要:
    已经合成了新颖的水霉素衍生的安古环素抗生素13a-d。使用乙酸2-硒代糖基乙酸酯7作为糖基供体的水霉素(6)的糖基化以优异的产率进行,但是尝试还原性去除硒烯基导致糖苷配基的重排或进一步芳构化。这些结果的结果,使从水霉素(6)开始制备乌达霉素B(10)成为可能。另外,在质子条件下,甲硅烷基保护的D-椭圆12a,b连接到水霉素(6)的C-糖苷结构域上。如所预期的,苯并[a]蒽骨架6的羟基和酚基在所用糖基化条件下不反应。从四丁基氟化铵开始逐步除去甲硅烷基保护基,然后使用HF /吡啶配合物抑制了糖苷配基的可能重排,并成功终止了序列。新的安古环素抗生素13a和13b是已知的一些最有效的黄嘌呤氧化酶抑制剂,并具有ED50值为12.6-2.9x 10(-6)M的细胞毒性。
    DOI:
    10.1016/s0968-0896(00)00166-8
  • 作为产物:
    描述:
    酒色霉素 A1盐酸 作用下, 以 为溶剂, 生成 水绫霉素
    参考文献:
    名称:
    Identification of the aglycon part of vineomycin A1 with aquayamycin.
    摘要:
    藤黄霉素 A1(原 OS-4742 A1)由 Streptomyces matensis subsp.通过温和水解得到的苷元部分与水霉素相同,并确定了其 13C-NMR 赋值。
    DOI:
    10.1248/cpb.29.1788
点击查看最新优质反应信息

文献信息

  • The absolute configuration of P-1894B, a potent prolyl hydroxylase inhibitor.
    作者:KAZUHIKO OHTA、EIJI MIZUTA、HISAYOSHI OKAZAKI、TOYOKAZU KISHI
    DOI:10.1248/cpb.32.4350
    日期:——
    The previous X-ray-crystallographic determination of the relative configuration of P-1894B, a potent prolyl hydroxylase inhibitor isolated from the culture broth of Streptomyces albogriseolus, was extended by means of chemical and spectral studies. The absolute configuration of P-1894B (1) was established from the absolute configuration of two constituent monosaccharides, L-aculose (3) and L-rhodinose (4), produced by chemical degradation of 1. The absolute configuration of the aglycone part (aquayamycin) was also established as 2. The stereostructure of the reduction product (11) obtained by the catalytic hydrogenation of 1 was also elucidated.
    之前对从白色链霉菌的培养液中分离出的强效脯氨酸羟化酶抑制剂P-1894B的相对构型的X射线晶体学测定,通过化学和光谱研究得到了进一步的扩展。通过对1的化学降解所产生的两个组成单糖L-果糖(3)和L-红糖(4)的绝对构型,确定了P-1894B(1)的绝对构型。糖苷部分(aquayamycin)的绝对构型也被确定为2。此外,还阐明了通过对1进行催化加氢反应获得的还原产物(11)的立体结构。
  • Preparation of prodrugs for selective drug delivery
    申请人:Mills L. Randell
    公开号:US20050080260A1
    公开(公告)日:2005-04-14
    Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.
    合成具有A-B-C化学式的化合物,可用于药物传递等应用,其中A是化学发光基团,B是光致变色基团,C是生物活性基团,其中A-B-C可作为前药。本发明的新型合成方法用于形成前药,包括以下步骤:(1)形成苯酮,(2)形成二芳基乙烯,(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上,形成邻苯二甲酰亚胺-乙烯共轭物,(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物,形成邻苯二甲酰亚胺-戊二烯共轭物,(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼,形成本发明的载体化合物,(6)将载体化合物与药物的亲核基团反应,形成相应的前药。另外,可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后,通过与亲核试剂反应保护阳离子类似化合物,并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联,形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流,将其邻苯二甲酰亚胺转化为邻苯二酰肼,并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂,用于治疗病毒感染,如HIV,以及用作抗癌剂,用于治疗结肠癌、肺癌和乳腺癌等癌症。
  • Total Synthesis of Aquayamycin
    作者:Shunichi Kusumi、Harunobu Nakayama、Takumi Kobayashi、Hajime Kuriki、Yuka Matsumoto、Daisuke Takahashi、Kazunobu Toshima
    DOI:10.1002/chem.201604697
    日期:2016.12.23
    An efficient and practical total synthesis of aquayamycin has been accomplished. The highly oxidized and stereochemically complex tetracyclic ring system was constructed using three key reactions: 1) highly diastereoselective 1,2‐addition of C‐glycosyl naphthyllithium to a cyclic ketone, 2) indium‐mediated site‐selective allylation‐rearrangement sequence of naphthoquinone, and 3) diastereoselective
    已经完成了高效且实用的水霉素全合成。高氧化和立体化学复杂的四环系统是通过以下三个关键反应构建的:1)C-糖基萘基锂与环酮的高非对映选择性1,2-加成;2)萘介导的铟介导的位点选择性烯丙基化重排序列; 3)非对映选择性分子内频哪醇偶联。这种合成策略为制备水霉素型安古环素抗生素提供了一种新颖而有效的途径。
  • Synthetic study of aquayamycin. Part 3: First total synthesis
    作者:Takashi Matsumoto、Hiroki Yamaguchi、Mitsujiro Tanabe、Yoshizumi Yasui、Keisuke Suzuki
    DOI:10.1016/s0040-4039(00)01480-5
    日期:2000.10
    The first total synthesis of aquayamycin (1) has been accomplished. The crucial steps include (1) the Hauser reaction between 3-(phenylsulfonyl)phthalide 3 and cyclohexenone 4 to make up the linear BCD tricycle, and (2) the intramolecular pinacol coupling of keto aldehyde 7 to the full tetracyclic framework.
    首次完成了水霉素(1)的全合成。关键步骤包括(1)3-(苯磺酰基)邻苯二甲酸酯3和环己烯酮4之间的Hauser反应,以组成线性BCD三环,以及(2)酮醛7的分子内频哪醇偶联到完整的四环骨架上。
  • The absolute configuration of P-1894B (vineomycin A1), a potent prolyl hydroxylase inhibitor.
    作者:Kazuhiko Ohta、Hisayoshi Okazaki、Toyokazu Kishi
    DOI:10.1248/cpb.30.762
    日期:——
    The absolute configuration of P-1894B (vineomycin A1 (I)), a potent prolyl hydroxylase inhibitor, has been established as I from the absolute configuration of two sugar moieties (II, VI) obtained by chemical degradation of I.
    P-1894B (藤黄霉素 A1 (I))是一种强效的脯氨酰羟化酶抑制剂,通过化学降解 I 得到的两个糖分子(II、VI)的绝对构型,确定其绝对构型为 I。
查看更多

同类化合物

酒色霉素 A1 萘并[1,2-b]菲-7,14-二酮 苯并蒽-7,12-二酮 腊伯罗霉素 浅内红霉素 水绫霉素 棣棠霉素 C 抑胃酶氨酰-21 富士霉素A 四角霉素 丙酸,2-甲基-,(3R,4S)-1,2,3,4,7,12-六氢-8-甲氧基-3-甲基-1,7,12-三羰基苯并[a]蒽-4-基酯 丁二酸,碘-,4-乙基1-甲基酯(9CI) N-{4-[(4-吡啶-2-基哌嗪-1-基)羰基]苯基}-7-(三氟甲基)喹啉-4-胺 8-羟基-3-甲基-3,4-二氢-1,7,12(2H)-苯并[a]蒽三酮 8-甲氧基-3-甲基-3,4-二氢-1,7,12(2H)-四苯e三酮 8,11-二[2-(2-羟基乙基氨基)乙基氨基]-6-甲氧基-1,2,3,4-四氢苯并[a]蒽-7,12-二酮 4a,8,12b-三羟基-4-甲基-1H-苯并[a]蒽-2,7,12-三酮 3-甲氧基苯并(a)蒽-7,12-二酮 1,3-二羟基-8-甲氧基-3-甲基-2,4-二氢-1H-苯并[a]蒽-7,12-二酮 (R)-8-羟基-3-甲基-1,2,3,4-四氢苯并[a]蒽-7,12-二酮 (3S)-6-羟基-8-甲氧基-3-甲基-3,4-二氢-2H-苯并[a]蒽-1,7,12-三酮 (3S)-3-甲基-8-[(2S,3R,4R,5R,6S)-3,4,5-三羟基-6-甲基四氢吡喃-2-基]氧基-3,4-二氢-2H-苯并[a]蒽-1,7,12-三酮 (3S)-11-羟基-8-甲氧基-3-甲基-3,4-二氢-2H-苯并[a]蒽-1,7,12-三酮 (3R)-9-[(2R,4R,5R,6R)-4-[(2S,5S,6S)-5-[(2S,4R,5S,6R)-4,5-二羟基-6-甲基四氢吡喃-2-基]氧基-6-甲基四氢吡喃-2-基]氧基-5-羟基-6-甲基四氢吡喃-2-基]-3,8-二羟基-3-甲基-2,4-二氢苯并[b]菲-1,7,12-三酮 (2S,4S,5S)-4-[(1E,3E,5E)-7-[(2R,6R)-6-[(2R,3S,4aR,12bS)-2,3,4A,8,12B-五羟基-3-甲基-1,7,12-三氧代-2,4-二氢苯并[h]菲-9-基]-2-甲基四氢吡喃-3-基]氧基-7-氧代庚-1,3,5-三烯基]-2,5-二甲基-1,3-二氧戊环-2-羧酸 (2R,3S,4aR,12bS)-2,3,4a,8,12b-五羟基-3-甲基-3,4,4a,12b-四氢-1,7,12(2H)-四苯e三酮 (1S,3S)-10-[[(1S,3S)-1,11-二羟基-8-甲氧基-3-甲基-7,12-二氧代-1,2,3,4-四氢苯并[h]菲-10-基]甲基]-1,11-二羟基-8-甲氧基-3-甲基-1,2,3,4-四氢苯并[B]菲-7,12-二酮 (1S,3S)-1-羟基-8-甲氧基-3-甲基-1,2,3,4-四氢苯并[a]蒽-7,12-二酮 (-)-8-O-甲基四角霉素 methyl 9-fluoro-6-hydroxy-8-methoxy-1,2,3,4-tetrahydrobenz[a]anthracene-7,12-dione-2-carboxylate urdamycinone B amycomycin B 6-hydroxy-5-hydroxymethylbenz[a]anthracene-7,12-dione 6-hydroxy-5-methylbenz[a]anthracene-7,12-dione 6-hydroxy-1,5,8-trimethoxy-3-methyltetraphene-7,12-dione 3,6-Dihydroxy-3-methyl-1,2,3,4-tetrahydrobenzanthracene-7,12-dione Moromycin B Moromycin A 1,2,3,11,12,13-Hexamethoxydibenzanthracen-7,14-chinon 4-methoxybenzanthracene-7,12-dione Fujianmycin B (3R,4aR,12bS)-4a,8,12b-trihydroxy-9-[5-(5-hydroxy-6-methyloxan-2-yl)oxy-6-methyloxan-2-yl]-3-methyl-3-[(6-methyl-5-oxo-2H-pyran-2-yl)oxy]-2,4-dihydrobenzo[a]anthracene-1,7,12-trione 4,11-dihydroxy-dibenz[a,h]anthracene-7,14-dione 5-fluoro-1,2,3,4-tetrahydrobenzanthracene-7,12-dione 10-fluoro-1,2,3,4-tetrahydrobenzanthracene-7,12-dione 3-methoxydibenzanthracene-7,14-dione 4-Hydroxy-benzanthracen-7,12-dion 8-Methoxy-1,2,3,4-tetrahydro-benzo[a]anthracene-7,12-dione 1-Hydroxybenzantracen-7,12-chinon 8-methoxy-3-methyl-7,12-dioxy-1,2,3,4-tetrahydro-benzoanthracene-2-dimethylene dithioacetal